{
    "clinical_study": {
        "@rank": "65719", 
        "brief_summary": {
            "textblock": "The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels\n      in the treatment of pancreatic cancer."
        }, 
        "brief_title": "Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer", 
        "completion_date": "December 2003", 
        "condition": "Pancreatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Disease Characteristics:\n\n          -  Patients with a documented histologic or cytologic diagnosis of a pancreatic\n             malignancy\n\n          -  Patients with recurrent, advanced and/or metastatic disease, who have either failed\n             standard therapy or are not eligible for any alternate therapies of higher\n             therapeutic priority.\n\n          -  Patients with at least one identified (confirmed) and measureable tumor site.\n\n        Prior/Concurrent Therapy:\n\n          -  Surgery: Patients are excluded if they have had major surgery either during or within\n             four weeks prior to study entry.\n\n          -  Chemotherapy: Patients must have failed standard therapy or are not eligible for any\n             alternate therapies of higher therapeutic priority.\n\n          -  Biologic Therapy: Patients who have received a chimeric, CDR-grafted (humanized), or\n             human IgG will be eligible provided pre-study evaluations demonstrate no significant\n             reactivity with hMN14 IgG (i.e., HAHA)\n\n          -  Radiotherapy: No prior radiotherapy within four weeks of study entry.  No prior\n             external beam irradiation to a field that includes more than 30% of the red marrow.\n             No prior radiation to maximal tolerable levels for any critical organ (e.g., 3,000\n             cGy for the liver; 2,000 cGy for the lungs and kidneys).\n\n          -  Other: Any experimental therapy (i.e., drugs, biologics, procedures) for the primary\n             malignancy, either during or within four weeks prior to study entry.\n\n        Patient Characteristics/Inclusion Criteria:\n\n          -  Performance Status: Patients with a Karnofsky performance status > 70% (or\n             equivalent, ECOG 0-1) and an expected survival rate of at least 3 months\n\n          -  Hematopoietic: Hemoglobin > 10g/dL; WBC > 3000 per mm3; Granulocyte count > 1500 per\n             mm3; platelet count > 100,000 per mm3\n\n          -  Hepatic: Total bilirubin < 1.5 times the institutional upper limit of normal (IULN);\n             AST or ALT < 2 X IULN\n\n          -  Renal: Creatinine < IULN\n\n          -  Cardiovascular: Patients with LVEF >/= 50% by required MUGA/2D-ECHO study\n\n          -  Pulmonary: Patients with DF and FEV1 >/= 60 % by required Pulmonary Function Tests\n\n          -  Gastrointestinal:Patients with severe anorexia or other related symptomology are\n             excluded\n\n          -  Central Nervous System: Patient with known metastatic disease to the CNS are excluded\n\n          -  Other: Patients who have had a prior imaging study with a murine antibody may be\n             included.  Patients agreeing to use a medically effective method of contraception\n             during and for a period of three months after the treatment period.  A pregnancy test\n             will be preformed on each premenopausal female of childbearing potential immediately\n             prior to entry into the study.  Patients able to understand and give written informed\n             consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "75", 
        "firstreceived_date": "July 11, 2002", 
        "id_info": {
            "nct_id": "NCT00041639", 
            "org_study_id": "IM-T-hMN14-03"
        }, 
        "intervention": {
            "intervention_name": "hMN14 (labetuzumab)", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Pancreatic Cancer", 
            "Pancreatic Carcinoma", 
            "Pancreatic Neoplasms", 
            "Pancreas Cancer", 
            "Pancreatic Tumor"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92658"
                    }, 
                    "name": "Hoag Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Washington Hospital Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33744"
                    }, 
                    "name": "Bay Pines VA Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101-2799"
                    }, 
                    "name": "Virginia Mason Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Medizinische Fakultaet der Charit\u00e9 Berlin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Universitaetsklinikum Leipzig"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Semmelweis University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary"
                    }, 
                    "name": "Medical University of Szeged"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Academic Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Hungary", 
                "Netherlands"
            ]
        }, 
        "official_title": "A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma", 
        "overall_official": {
            "affiliation": "Immunomedics, Inc.", 
            "last_name": "William Wegener, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00041639"
        }, 
        "source": "Immunomedics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunomedics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2004"
    }, 
    "geocoordinates": {
        "Academic Medical Center": "52.37 4.895", 
        "Bay Pines VA Medical Center": "27.773 -82.64", 
        "Hoag Cancer Center": "33.619 -117.929", 
        "Medical University of Szeged": "46.254 20.146", 
        "Medizinische Fakultaet der Charit\u00e9 Berlin": "52.524 13.406", 
        "Semmelweis University": "47.498 19.041", 
        "Universitaetsklinikum Leipzig": "51.349 12.394", 
        "University of Pittsburgh Cancer Institute": "40.441 -79.996", 
        "Virginia Mason Medical Center": "47.606 -122.332", 
        "Washington Hospital Center": "38.895 -77.036"
    }
}